Pfizer Provides Topline Results From Phase 3 Study Of Torisel(R) As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) – Marketwatch

Strong inducers of CYP3A4/5 (eg, dexamethasone, rifampin) and strong inhibitors of CYP3A4 (eg, ketoconazole, atazanavir) may decrease and increase concentrations of the major metabolite of TORISEL, respectively. If alternatives cannot be used …